Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
about
Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib.The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011.Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature.Refining sorafenib therapy: lessons from clinical practice.Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib.Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib.Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma.Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma.Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma.Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular CarcinomaLong-term remission in advanced stage hepatocellular carcinoma? A chance for cure?
P2860
Q37641084-E3996935-D38E-4DD8-8A26-C21F82F433B9Q37995237-17319924-61E5-4A18-86FA-A828470A5ED2Q38068868-2B639CD4-7CB8-4B58-BEC9-39831FC78900Q38264146-035BADED-AA2E-41AD-8374-598E96F573F5Q38427724-479B8048-FDBC-425B-B7F6-D7FDD41D6052Q39276331-1524A358-EA60-4814-8338-2F55FB875204Q39374939-8EF5F32B-9E27-4537-9A93-521850CEC837Q40246883-265FFCEC-A6D0-45E5-A40A-ED2CD1691765Q40424405-B75D6F3B-C1D8-4C0E-8AB7-C1956AF71550Q41853963-70F76BE9-26D8-4615-A745-9546EA0A9E8EQ42136590-A7E1C22D-A701-4629-8BF8-AE24F03815F0Q43244774-7CBFA36B-7FE7-4C66-83E1-CCD447B8B98FQ43608014-B0F0C8D7-F3B9-4CDA-8CBE-36D4885C2B97Q43804593-BC4499CF-C2FF-42B0-87C9-B065CE466723Q48853960-E2F99296-0961-4082-A136-3D284BEDDE5EQ50453658-B7ECDC2A-6C6D-43BF-A724-3E5145A5D8F6Q50492074-891E0F41-4F74-422F-A88F-3428CBC18B2BQ57943770-E1698AF4-0172-4B05-BF3B-F131E820796BQ58704728-A601609A-D06B-463D-A706-5218450190C3
P2860
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Optimized management of advanc ...... asting responses to sorafenib.
@en
Optimized management of advanc ...... asting responses to sorafenib.
@nl
type
label
Optimized management of advanc ...... asting responses to sorafenib.
@en
Optimized management of advanc ...... asting responses to sorafenib.
@nl
prefLabel
Optimized management of advanc ...... asting responses to sorafenib.
@en
Optimized management of advanc ...... asting responses to sorafenib.
@nl
P2093
P2860
P356
P1476
Optimized management of advanc ...... asting responses to sorafenib.
@en
P2093
Armando Santoro
Cynthia Carrillo-Infante
Emanuele Cucchi
Giovanni Abbadessa
Tiziana Pressiani
P2860
P304
P356
10.3748/WJG.V17.I19.2450
P407
P577
2011-05-01T00:00:00Z